Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration‐resistant prostate cancer treated with Radium‐223

Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration‐resistant prostate cancer treated with Radium‐223

Abstract Background In men with metastatic castration‐resistant prostate cancer (mCRPC) with primarily bone metastases, radium‐223 (223Ra) improves overall survival (OS). However, the selection of 223Ra is not guided by specific validated clinicopathologic factors, and thus outcomes are heterogeneou...

Full description

Bibliographic Details
Main Authors: Esmail M. Al‐Ezzi, Husam A. Alqaisi, Marco A. J. Iafolla, Lisa Wang, Srikala S. Sridhar, Adrian G. Sacher, Nazanin Fallah‐Rad, Di M. Jiang, Geoffrey A. Watson, Charles N. Catton, Padraig R. Warde, Rob J. Hamilton, Neil E. Fleshner, Alexandre R. Zlotta, Aaron R. Hansen
Format: Article
Language:English
Published: Wiley 2021-09-01
Series:Cancer Medicine
Subjects:
clinical management
neoplasms
prognostic factors
prostate cancer
risk model
survival
Online Access:https://doi.org/10.1002/cam4.4125

Internet

https://doi.org/10.1002/cam4.4125

Similar Items